Why Medical Marijuana Caused GW Pharmaceuticals to Climb 10% in November

What: Ahead of data from trials evaluating its marijuana-derived therapies for the treatment of epilepsy, shares in GW Pharmaceuticals (NASDAQ:GWPH) increased by 10.5% in November.

So what: Perhaps no other company is as focused on using marijuana to develop medicine as GW Pharmaceuticals.

The company already has one THC drug, Sativex, on the European market as a treatment for multiple sclerosis muscle spasms. GW's marijuana studies include the evaluation of the marijuana cannabidiol CBD for the treatment of Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy.

GW Pharmaceuticals is expected to release data from ongoing late-stage trials in these indications in Q1. If those results are positive, then its drug, Epidiolex, may offer newfound hope to thousands of patients; earlier this year, the company reported that patients participating in a non-placebo controlled study experienced 52% fewer seizures when taking Epidiolex for 12 weeks.

Now what: In September, the company...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.